Evaluation of statin utilisation in tertiary care teaching hospital: An observational prospective study, YSR Kadapa
Abstract
ABSTRACT
Introduction: Statins are highly preferred drugs in the treatment and prevention of atherosclerotic diseases. Statins usage increased in the last two decades. DUE is a cyclic quality-enhancing procedure in the prescription of drugs.
Methods: Our study engaged in compiling various prescribing conditions for statins, assessing their effectiveness and safety, and comparing the lipid profile images of atorvastatin and rosuvastatin. A prospective observational study with the involvement of 150 volunteers The complete data collected is analysed using SAS and Microsoft Excel software. Statistical methods of mean, standard deviation, clinical significance, and Z value are calculated.
Results: Atorvastatin (20 mg, 40 mg, and 80 mg) and Rosuvastatin (5 mg and 10mg) are widely used in the primary, secondary, and tertiary prevention of atherosclerotic cardiovascular and cerebrovascular problems. Average reduction of LDL and total cholesterol levels to 106.5(SD ±11.04) and 203.53 (SD±94) respectively.
Conclusion: Both drugs are equally effective in reducing cholesterol levels. adverse drug reactions observed on long-term usage of 2 to 6 years in 7.33% of volunteers Secondary and tertiary occurrences of CVA are observed due to non-adherence.
Key words: Atorvastatin, cardiovascular and cerebrovascular problems, non
adherence, Re-occurrence, Rosuvastatin.
Downloads
References
Al-Shura, A. N. (2014). Hematology in Traditional Chinese Medicine Cardiology. Elsevier.
Berne, C., & Siewert-Delle, A. (2005). Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovascular Diabetology, 4(1), 1-11.
Bernini, F., Poli, A., & Paoletti, R. (2001). Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. Cardiovascular drugs and therapy, 15, 211-218.
Chaiyakunapruk, N., Asuphol, O., Dhippayom, T., Poowaruttanawiwit, P., & Jeanpeerapong, N. (2011). Statins utilisation pattern: a retrospective evaluation in a tertiary care hospital in Thailand. International Journal of Pharmacy Practice, 19(2), 129-135.
Choudhry, N. K., Dugani, S., Shrank, W. H., Polinski, J. M., Stark, C. E., Gupta, R., ... & Jha, P. (2014). Despite increased use and sales of statins in India, per capita prescription rates remain far below high-income countries. Health Affairs, 33(2), 273-282.
El-Gohary, T. M., Alshenqiti, A. M., Ibrahim, S. R., Khaled, O. A., Ali, A. R. H., & Ahmed, M. S. (2019). Risk factors and types of recurrent stroke: a Saudi hospital based study. Journal of Physical Therapy Science, 31(10), 743-746.
Gaddi, A., Cicero, A. F. G., Odoo, F. O., Poli A, A., Paoletti, R., & Atherosclerosis and Metabolic Diseases Study Group. (2007). Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vascular health and risk management, 3(6), 877-886.
Golomb, B. A., & Evans, M. A. (2008). Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. American Journal of Cardiovascular Drugs, 8, 373-418.
Lee, M., Saver, J. L., Wu, Y. L., Tang, S. C., Lee, J. D., Rao, N. M., ... & Ovbiagele, B. (2017). Utilization of Statins Beyond the Initial Period After Stroke and 1‐Year Risk of Recurrent Stroke. Journal of the American Heart Association, 6(8), e005658.
Manoj, K., Jain, N., & Madhu, S. V. (2017). Myopathy in patients taking atorvastatin: a pilot study. Indian Journal of Endocrinology and Metabolism, 21(4), 504.
Mazzaglia, G., & Mol, P. (2016). Drug utilization research and risk management. Drug Utilization Research: Methods and Applications, 392-398.
Nanna, M. G., Wang, T. Y., Xiang, Q., Goldberg, A. C., Robinson, J. G., Roger, V. L., ... & Navar, A. M. (2019). Sex differences in the use of statins in community practice: patient and provider assessment of lipid management registry. Circulation: Cardiovascular Quality and Outcomes, 12(8), e005562.
Nayak-Rao, S., & Shenoy, M. P. (2017). Stroke in patients with chronic kidney disease…: How do we approach and manage it?. Indian journal of nephrology, 27(3), 167.
Pasha, M. K., Muzeeb, S., Basha, S. J. S., Shashikumar, D., Mullangi, R., & Srinivas, N. R. (2006). Analysis of five HMG‐CoA reductase inhibitors—atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. Biomedical Chromatography, 20(3), 282-293.
Praveen, K. G., & Arun, K. (2013). Drug utilization and evaluation of HMG-co A reductase inhibitors in tertiary care teaching hospital. Indian journal of pharmacy practice, 6(4).
Ramkumar, S., Raghunath, A., & Raghunath, S. (2016). Statin therapy: review of safety and potential side effects. Acta cardiologica sinica, 32(6), 631.
Ransam, M., Vincent, M., Swathy, C. J., Krishnakumar, K., Baby, M., & Varghese, A. (2019). A STUDY ON DRUG UTILISATION REVIEW OF CARDIOVASCULAR DISEASES. Acta Biomedica Scientia e-ISSN, 2348, 2168.
Statin Drugs May Increase Risk Of Peripheral Neuropathy. (2002, May 2). ScienceDaily. https://www.sciencedaily.com/releases/2002/05/020514075710.htm
Sundvall, H., Fastbom, J., Wallerstedt, S. M., & Vitols, S. (2019). Use of statins in the elderly according to age and indication—a cross-sectional population-based register study. European Journal of Clinical Pharmacology, 75, 959-967.
Teeling, M., Bennett, K., & Feely, J. (2005). The influence of guidelines on the use of statins: analysis of prescribing trends 1998–2002. British journal of clinical pharmacology, 59(2), 227-232.
Vitturi, B. K., & Gagliardi, R. J. (2020). The influence of statins on the risk of post-stroke epilepsy. Neurological Sciences, 41, 1851-1857.
Yebyo, H. G., Aschmann, H. E., Kaufmann, M., & Puhan, M. A. (2019). Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. American heart journal, 210, 18-28.
Yourman, L. C., Cenzer, I. S., Boscardin, W. J., Nguyen, B. T., Smith, A. K., Schonberg, M. A., ... & Lee, S. J. (2021). Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis. JAMA internal medicine, 181(2), 179-185.
Copyright (c) 2023 Suchitra Uppicherla, Divya Sree Tadimarri, Nandha Kumar K. N., Haritha Rajaboyna, K. D. Yadavendra Reddy, Gowtham Kumar Reddy Ponnolu, Rajaram Cuddapah, Jeevan Kumar B.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
